Bristol Myers Squibb (BMY) Expected to Post Quarterly Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY) is projected to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of $1.10 per share and revenue of $12.72 billion for the quarter. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 earnings per share. On average, analysts expect Bristol Myers Squibb to post $6.51 EPS for the current fiscal year and $6.50 EPS for the next fiscal year.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $61.63 on Wednesday. The business’s 50 day moving average price is $63.09 and its 200-day moving average price is $59.85. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Encouraging cancer-drug data strengthens the growth pipeline. Izalontamab brengitecan (Iza-Bren) reportedly doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer. Separate Phase 3 data indicated the drug reduced breast-cancer progression risk by as much as 38%. The results could support a future growth driver as Bristol Myers Squibb manages declines from older products. Iza-Bren lung cancer trial results
• Positive Sentiment: Valuation remains supportive. One analysis argues that BMY still trades below fair value based on expected future cash generation, despite its strong 12-month advance. Analysts also point to growth medicines and higher Eliquis guidance as potential offsets to legacy-portfolio weakness. BMY valuation analysis
• Neutral Sentiment: Third-quarter earnings are the next major catalyst. Preview coverage is focused on revenue trends, Eliquis performance, newer growth products and the pace of decline in older drugs. The market is waiting to see whether operating results support the company’s full-year EPS guidance of $6.75–$7.00. Q3 earnings preview
• Neutral Sentiment: Analyst sentiment is cautious but not bearish. Piper Sandler lowered its price target from $82 to $78 while retaining an Overweight rating, implying further upside. Zacks Research maintains a Hold rating and trimmed its Q3 2027, FY2027 and FY2028 EPS estimates only slightly, to $1.55, $6.23 and $5.21, respectively. Piper Sandler BMY target
• Negative Sentiment: Patent expirations remain the principal risk. Declining sales from key legacy medicines could pressure earnings, and estimates already imply lower profitability in later years. Investors must weigh the pipeline’s commercialization potential against this erosion. BMY bargain or value trap analysis

Analysts Set New Price Targets

BMY has been the topic of a number of recent analyst reports. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $71.00 to $66.00 in a research report on Friday, October 9th. Raymond James Financial assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Cantor Fitzgerald cut their target price on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research note on Thursday, October 8th. TD Cowen began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating on the stock. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a report on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $65.50.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.